ESBATech
Schlieren · Founded 1998
About ESBATech
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
Company Facts
- Founded: 1998
- Legal name: ESBATech AG
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $72.0M
- Funding stage: M&A
- Last round: Series B (Aug 2008)
- Website: esbatech.com
- Phone: +41447334990
Social Profiles
Canonical: https://fsome.com/organization/esbatech-8418430 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.